Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial

Journal:

Nature Medicine

Published:

2025-07-30

DOI:

10.1038/s41591-025-03843-z

Affiliations:

9

Authors:

13

Go to article

Institutions	Authors	Share
Merck Group, Germany	4.000000	0.31
The University of Texas MD Anderson Cancer Center, United States of America (USA)	2.000000	0.15
Hospital Universitario Quirónsalud Madrid, Spain	1.000000	0.08
National Cancer Center Hospital, Japan	1.000000	0.08
Vall d'Hebron University Hospital (HUVH), ICS, Spain	1.000000	0.08
Merck Serono S.A.S., France	1.000000	0.08
Merck Chemicals Ltd., United Kingdom (UK)	1.000000	0.08
Ares Trading S.A., Switzerland	1.000000	0.08
NEXT Oncology, United States of America (USA)	1.000000	0.08

Interested in Oncology and Carcinogenesis?